中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2001 records (took 0.063 seconds)

    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME
    36.
    发明申请
    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开

    公开(公告)号：US20160368958A1

    公开(公告)日：2016-12-22

    申请号：US15197278

    申请日：2016-06-29

    Applicant: OncoTherapy Science, Inc.

    Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OHSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

    IPC: C07K14/47 ,  C07K16/18

    CPC classification number: C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

    IMP-3 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME
    37.
    发明申请
    IMP-3 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME 有权
    IMP-3用于TH1细胞的EPITOPE肽和含有它的疫苗

    公开(公告)号：US20160114018A1

    公开(公告)日：2016-04-28

    申请号：US14890146

    申请日：2014-05-22

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yasuharu NISHIMURA ,  Yusuke TOMITA ,  Masatoshi HIRAYAMA ,  Ryuji OSAWA

    IPC: A61K39/00

    CPC classification number: A61K39/0011 ,  A61K31/7088 ,  A61K35/17 ,  A61K35/26 ,  A61K38/00 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/65 ,  A61K2300/00

    Abstract: Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer, cervical cancer, cholangiocellular carcinoma, chronic myelocytic leukemia, colon cancer, rectum cancer, esophageal cancer, gastric diffuse-type cancer, non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), lymphoma, osteosarcoma, ovarian cancer, renal carcinoma, soft tissue tumor, testicular tumor, and HNC.

    Abstract translation: 本文公开了具有Th1细胞诱导能力的分离的IMP-3衍生的表位肽。 这样的肽可被MHC II类分子识别并诱导Th1细胞。 在优选的实施方案中，本发明的这种肽可以与MHC II类分子混合结合并诱导除Th1细胞之外的IMP-3-特异性细胞毒性T淋巴细胞（CTL）。 因此，这样的肽适合用于增强受试者的免疫应答，并因此在癌症免疫治疗中尤其是用作癌症疫苗时使用。 本文还公开了编码由这些肽诱导的上述肽，APC和Th1细胞中的任何一种的多核苷酸以及与其相关的诱导方法。 包含任何前述组分作为活性成分的药物组合物可用于治疗和/或预防癌症或肿瘤，包括例如膀胱癌，宫颈癌，胆管细胞癌，慢性骨髓性白血病，结肠癌，直肠癌，食管癌 癌症，胃弥漫型癌，非小细胞肺癌（NSCLC），小细胞肺癌（SCLC），淋巴瘤，骨肉瘤，卵巢癌，肾癌，软组织肿瘤，睾丸肿瘤和HNC。

    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME
    39.
    发明申请
    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    TOPK PEPTIDES和疫苗，包括它们

    公开(公告)号：US20140255437A1

    公开(公告)日：2014-09-11

    申请号：US14353261

    申请日：2012-10-25

    Applicant: c/o ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama

    IPC: A61K39/00 ,  C07K16/18 ,  C07K7/06

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/0005 ,  A61K2039/5154 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/34 ,  C12N9/12 ,  C12N9/1205 ,  C12Y207/12002 ,  G01N33/505 ,  G01N33/574

    Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.

    Abstract translation: 本发明提供了源自TOPK的分离的表位肽，其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，更特别地，作为癌症疫苗。 本发明的肽包括包括TOPK衍生的氨基酸序列和其修饰形式的两种肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，只要这些修饰版本具有CTL 诱导性。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物组合物。 本发明的肽，多核苷酸和药物组合物在治疗和预防多种癌症中的任一者或两者中都具有特别的用途。

    GENES AND POLYPEPTIDES RELATING TO BREAST CANCERS
    40.
    发明申请
    GENES AND POLYPEPTIDES RELATING TO BREAST CANCERS 审中-公开
    与乳腺癌相关的基因和多肽

    公开(公告)号：US20140228238A1

    公开(公告)日：2014-08-14

    申请号：US14162487

    申请日：2014-01-23

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke NAKAMURA ,  Toyomasa KATAGIRI ,  Shuichi NAKATSURU

    IPC: G01N33/574 ,  C07K16/18 ,  G01N33/50 ,  C07K14/47

    CPC classification number: C07K16/18 ,  A61K31/7088 ,  C07K14/47 ,  C07K14/4748 ,  C12N2310/14 ,  C12Q1/485 ,  G01N33/5011 ,  G01N33/5035 ,  G01N33/57415 ,  G01N2333/9121 ,  G01N2510/00

    Abstract: The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.

    Abstract translation: 本申请提供了新的人类基因A7322，其表达在乳腺癌中显着升高。 本申请还提供了人类基因F3374，其在乳腺癌中的表达显着升高。 由此编码的这些基因和多肽可用于例如乳腺癌的诊断，以及用于开发针对乳腺癌的药物的靶分子。 本发明的特征在于筛选PBK / TOPK的激酶活性的调节剂的方法。 本发明还提供筛选用于预防或治疗癌症（例如乳腺癌）的药剂的方法。

Patent Agency Ranking